Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02372409
Recruitment Status : Recruiting
First Posted : February 26, 2015
Last Update Posted : May 23, 2019
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
By employing a combination of advanced MRI techniques and correlative serum biomarkers of blood brain barrier (BBB) disruption, the investigators plan to develop a powerful, first of its kind clinical algorithm in pediatrics whereby the investigators can measure and identify the window of maximal BBB disruption post MLA to 1) allow for an alternative to surgery in incompletely resected tumors, 2) allow for optimal chemotherapeutic dosing to achieve the greatest benefits and the least systemic side effects and 3) distinguish subsequent tumor progression from long-term MLA treatment effects. Preliminary data in adult imaging studies have shown that the BBB disruption lasts for several weeks following treatment before returning to a low baseline. This pilot therapeutic study will provide preliminary validation in pediatric patients.

Condition or disease Intervention/treatment Phase
Glioma Pilocytic Astrocytoma Anaplastic Astrocytoma Glioblastoma Mixed Oligoastrocytoma Mixed Glioma Oligodendroglioma Optic Glioma Astrocytoma Device: MRI-guided laser ablation Drug: Doxorubicin Drug: Etoposide Device: Dynamic contrast-enhanced (DCE) MRI Device: Dynamic susceptibility contrast (DSC) MRI Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Actual Study Start Date : August 14, 2015
Estimated Primary Completion Date : October 30, 2020
Estimated Study Completion Date : October 30, 2020


Arm Intervention/treatment
Experimental: Arm A (MRI-guided laser ablation)
  • MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.
  • Participants will undergo DCE and DSC-MRI imaging at the following time points:

    • no more than 3 weeks prior to MLA (OPTIONAL)
    • within approximately 4 days after MLA
    • 2-4 weeks after MLA
    • Every 12 weeks (+/- 7 days) for the first year or until disease progression
Device: MRI-guided laser ablation
Other Name: MLA

Device: Dynamic contrast-enhanced (DCE) MRI
Other Name: DCE-MRI

Device: Dynamic susceptibility contrast (DSC) MRI
Other Name: DSC-MRI

Experimental: Arm B (MRI-guided laser ablation, doxorubicin, etoposide)
  • MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.
  • Within 7 days of MLA (range 2-14 days) doxorubicin will be given intravenously on an outpatient basis weekly for 6 weeks at a dose of 25 mg/m^2 over 5-30 minutes
  • Following the completion of doxorubin, etoposide 50 mg/m^2/day will be given orally for 21 days of each 28-day cycle (treatment can continue up to 24 cycles)
  • Participants will undergo DCE and DSC-MRI imaging at the following time points:

    • no more than 3 weeks prior to MLA (OPTIONAL)
    • within approximately 4 days after MLA
    • 2-4 weeks after MLA
    • every 8 weeks (+/- 7 days) until 2 years have elapsed or disease progression, whichever comes first
Device: MRI-guided laser ablation
Other Name: MLA

Drug: Doxorubicin
Other Name: Adriamycin

Drug: Etoposide
Other Names:
  • Etoposide phosphate
  • VP-16
  • Toposar
  • Etopophos
  • VePesid

Device: Dynamic contrast-enhanced (DCE) MRI
Other Name: DCE-MRI

Device: Dynamic susceptibility contrast (DSC) MRI
Other Name: DSC-MRI




Primary Outcome Measures :
  1. Arm A only: Progression-free survival (PFS) [ Time Frame: Up to 5 years ]
    PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.

  2. Arm A only: Overall survival (OS) [ Time Frame: Up to 5 years ]
  3. Arm B only: Progression-free survival (PFS) [ Time Frame: 6 months ]
    PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.

  4. Arm B only: Quality of life (QOL) [ Time Frame: 1 year from MLA ]
    -Using Karnofsky or Lansky performance status in patients following MLA and in patients who receive doxorubicin and maintenance etoposide after MLA.


Secondary Outcome Measures :
  1. Correlation of MR imaging with peritumoral BBB disruption [ Time Frame: 1 year from MLA ]
    The linear regression model will used to investigate the correlation between MR imaging and peritumoral BBB disruption. To account for correlation among the repeated measures from the same patient, the longitudinal data will be analyzed with the use of linear generalized estimating equation (GEE). Whether the average measurements differ at the multiple time points will be evaluated through GEE model. Least-square means at each time points will be presented and standard errors will be calculated within the use of the GEE sandwich method when accounting for within-patient correlation.

  2. Serum biomarkers of peritumoral BBB disruption [ Time Frame: 1 year from MLA ]
    Since the investigators do not know which biomarkers will have better correlation with the Ktrans data from DCE and DSC-MRI and patients' survival outcome, the investigators plan to determine the levels of all 3 biomarkers in a blinded fashion. Once both the Ktrans and biomarker levels are available, the investigators will determine which biomarkers have the closest correlation that is statistically significant with the Ktrans. Pearson correlation coefficient (r) will be determined for each biomarker and Ktrans value. Biomarkers with higher correlation coefficient (r approaching 1) will be given higher priority.

  3. Predictive value of the peritumoral permeability score for patient outcome as measured by PFS [ Time Frame: 6 months ]
    Biomarkers with higher correlation coefficient (r approaching 1) will be given higher priority. A minimum r=0.5 is required for inclusion for further analysis and will be used as a peritumoral permeability score. This score will then be correlated with the patient outcome data (as measured by 6 month PFS rate) to determine whether it has a predictive value.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

ARM A

  • Presumed pediatric gliomas (grades I-IV) on MRI that are determined to be candidates for MLA by the treating neurosurgeon
  • Age 3 to ≤ 21
  • Karnofsky/Lansky performance status ≥ 60%

ARM B

  • Recurrent pediatric brain tumors determined candidates for MLA as determined by the treating neurosurgeon.
  • Unequivocal evidence of tumor progression by MRI
  • There must be an interval of at least 12 weeks from the completion of radiotherapy to study registration except if there is unequivocal evidence for tumor recurrence per RANO criteria. When the interval is less than 12 weeks from the completion of radiotherapy, the use of PET scan is allowed to differentiate between evidence of tumor recurrence and pseudoprogression.
  • Recurrent lesions with dimension and contour that are determined by the treating neurosurgeon to be appropriate for MLA.
  • Age 3 to ≤ 21
  • Karnofsky/Lansky performance status ≥ 60%
  • Adequate cardiac function as determined by a shortening fraction ≥ 27% or left ventricular ejection fraction ≥ 50% by echocardiogram within the past 1 year prior to registration.
  • Prior anthracycline therapy does not exceed 200 mg/m^2 total cumulative dose.
  • Adequate bone marrow and hepatic function as defined below (must be within 7 days of MLA):

    • Absolute neutrophil count (ANC) ≥ 1000/mcl (G-CSF is allowed)
    • Platelets ≥ 100 K/cumm
    • Hemoglobin ≥ 9 g/dL (pRBC transfusion +/- ESA are allowed)
    • ALT ≤ 3 x ULN
    • AST ≤ 3 x ULN
    • ALP ≤ 3 x ULN. If ALP is > 3 x ULN, GGT must be checked and be ≤ 3 x ULN.
    • Bilirubin ≤ 2 x ULN
  • At the time of registration, patient must have recovered from the toxic effects of prior therapy to no more than grade 1 toxicity.
  • At the time of registration, patient must be at least 4 weeks from other prior cytotoxic chemotherapy.
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

ARM A

  • Currently receiving or scheduled to receive any other therapies intended to treat the newly diagnosed glioma prior to MLA and the first post-MLA blood collection for correlative studies.
  • Multi-focal or metastatic disease.
  • Pregnant and/or breastfeeding. Premenopausal women must have a negative serum or urine pregnancy test within 14 days of study entry.
  • Inability to undergo MRI due to personal or medical reasons.
  • Known history of HIV or autoimmune diseases requiring immunosuppressant drugs.

ARM B

  • Prior treatment with bevacizumab within 12 weeks of study entry.
  • Previous treatment with complete cumulative doses of daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones that is equivalent to a total dose of > 200 mg/m2 doxorubicin.
  • More than 2 prior relapses (not counting the current relapse being treated on this study).
  • Currently receiving any other investigational agents that are intended as treatments of the relapsed tumor.
  • Multi-focal or metastatic disease.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, recent heart attack within the previous 12 months or severe heart problems, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant and/or breastfeeding. Premenopausal women must have a negative serum or urine pregnancy test within 14 days of study entry.
  • Inability to undergo MRI due to personal or medical reasons.
  • Known history of HIV or autoimmune diseases requiring immunosuppressant drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02372409


Contacts
Layout table for location contacts
Contact: Karen Gauvain, M.D. (314) 454-4457 gauvaink@wustl.edu

Locations
Layout table for location information
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Karen Gauvain, M.D.    314-454-4457    gauvaink@wustl.edu   
Principal Investigator: Karen Gauvain, M.D.         
Sub-Investigator: David Limbrick, M.D.         
Sub-Investigator: Joshua Shimony, M.D., Ph.D.         
Sub-Investigator: Gavin Dunn, M.D., Ph.D.         
Sub-Investigator: Joshua Rubin, M.D., Ph.D.         
Sub-Investigator: Allison King, M.D., M.P.H.         
Sub-Investigator: Eric Leuthardt, M.D.         
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Layout table for investigator information
Principal Investigator: Karen Gauvain, M.D. Washington University School of Medicine

Additional Information:
Publications:

Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT02372409     History of Changes
Other Study ID Numbers: 201502062
First Posted: February 26, 2015    Key Record Dates
Last Update Posted: May 23, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Glioma
Astrocytoma
Oligodendroglioma
Optic Nerve Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases
Optic Nerve Neoplasms
Cranial Nerve Neoplasms
Peripheral Nervous System Neoplasms
Cranial Nerve Diseases
Optic Nerve Diseases
Eye Diseases
Doxorubicin
Liposomal doxorubicin
Etoposide
Etoposide phosphate
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors